U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07105449) titled 'THC Titration of High-Potency Cannabis Concentrates' on May 27.
Brief Summary: High-potency cannabis use is associated with public health risks, such as cannabis use disorder, psychotic disorders, and impaired cognition. Legal markets in the US and Canada are geared towards the commercialization of high-tetrahydrocannabinol (THC) products, including concentrates as high as 90-95%. The cannabis industry has resisted regulation of higher-potency products claiming that cannabis consumers naturally self-titrate their use, but the limited evidence to date suggests that even though consumers may use less cannabis as potency rises, consumin...